pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,019 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
    Here is some of what you may have missed from the world's largest cancer research meeting.
    STAT · 1mo ago↗ source
  • STAT+: At the world’s largest cancer research meeting, data briefly took a backseat to grief
    At the world's largest cancer research meeting, new data were plentiful. But this year, there was also a focus on grief.
    STAT · 1mo ago↗ source
  • As FDA misses deadline on electric shock ban, disability advocates speak out
    The FDA has missed a self-imposed deadline to ban the use of electrical shock devices in people with intellectual disabilities.
    STAT · 1mo ago↗ source
← prev
page 22 of 41
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: Medicare’s mum on GLP-1s, and Massachusetts sues United
    We've been asking Medicare for weeks about the cost of giving seniors $50 obesity drugs.
    STAT · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
    Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months
    STAT · 1mo ago↗ source
  • Opinion: What should hospitals do when patients demand unvaccinated donor blood?
    “You have to understand a person's belief if you want to address it,” Deva Sharma says on the “First Opinion Podcast” about requests for unvaccinated donor blood.
    STAT · 1mo ago↗ source
  • STAT+: A turning point for pancreatic cancer patients
    Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • CDC says containing the spread of Ebola is top priority
    The Trump administration disregards infectious disease playbook, CEPI offers vaccine funding, and other health news from Morning Rounds
    STAT · 1mo ago↗ source
  • STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
    The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
    STAT · 1mo ago↗ source
  • Opinion: The military’s medical corps has a serious recruitment problem
    Congress must incentivize more physicians (and their employers) to join the military medical corps, writes the former attending physician to Congress.
    STAT · 1mo ago↗ source
  • Opinion: Medical schools diversified. So where are all the diverse doctors?
    Why are residency programs disciplining and dismissing trainees in a system funded to train them?
    STAT · 1mo ago↗ source
  • STAT+: Executives reveal tech initiatives at Summa Health, eight months after General Catalyst acquisition
    Two years after General Catalyst said it was buying Ohio safety-net hospital Summa Health, executives shed light on how the “transformation” is going.
    STAT · 1mo ago↗ source
  • STAT+: Medicare still won’t say how much covering obesity drugs will cost
    Older adults on Medicare can get Wegovy and Zepbound for $50 a month, starting in July. But the agency still is not sharing how much this will cost taxpayers.
    STAT · 1mo ago↗ source
  • The hidden history of BPC-157, a favorite MAHA peptide
    A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.
    STAT · 1mo ago↗ source
  • STAT+: No Surprises Act arbitration rule could worsen flood of provider disputes
    The arbitration process has protected patients but generated financial windfalls for some clinicians.
    STAT · 1mo ago↗ source
  • STAT+: A standing ovation for RevMed, and caution for Akeso
    ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
    STAT · 1mo ago↗ source
  • Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
    Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
    STAT · 1mo ago↗ source
  • STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
    Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
    STAT · 1mo ago↗ source
  • STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
    A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
    STAT · 1mo ago↗ source
  • STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
    By doing hormone therapy upfront in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
    STAT · 1mo ago↗ source
  • STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
    ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
    STAT · 1mo ago↗ source
  • STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says
    Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as…
    STAT · 1mo ago↗ source
  • STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
    CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
    STAT · 1mo ago↗ source
  • STAT+: As Ebola outbreak grows, Trump administration veers from previous government playbook
    Trump officials are disregarding the Biden administration's detailed pandemic plans in favor of their own strategy.
    STAT · 1mo ago↗ source
  • STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
    You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here.   We’re ASCOmaxxing. Rest…
    STAT · 1mo ago↗ source